Healthcare PE Below Average, Turning with Catalysts (QNRX, BXRX, WHSI, SPRO, AQST)

Over the past 12 months earnings and revenue in the healthcare sector are up 31%, and conversely market cap is down 19%.  The PE ratio in the sector has dropped from 57x to 36x.   The 3 year average PE for the sector is 48, this has created a bunch of value opportunity for healthcare investors.

As the summer comes to a close Monkeypox, Long COVID and other unique healthcare challenges have brought the spotlight back to the sector.  


Healthcare, particularly Healthtech, Biotech and Pharma has some of the best opportunities for speculators.  It is the rare industry where a pre-revenue company can double its market cap overnight based on a catalyst.

Some stocks in the sector are already on fire.  

  • Quoin Pharmaceuticals (Nasdaq: QNRX) gained over 20% Tuesday night, the company announced it closed an equity offering raising $15 million for its clinical efforts.   
  • Baudax Bio, Inc. (Nasdaq: BXRX) was also up overnight (12.38%) although the stock still remains well off its August highs after announcing the closing of a $6.2 million public offering on September 1st.
  • Spero Therapeutics (Nasdaq: SPRO) was up 55% Tuesday on positive FDA news regarding its Phase 3 clinical trial for tebipenem HBr which treats complicated urinary tract infections. 
  • Aquestive Therapeutics (Nasdaq: AQST) was up 8.8% overnight Tuesday, but there is no obvious catalyst.


Healthcare investors know that the key to realizing ‘healthy’ profits is the proper anticipation of catalysts.  There are several speculative healthcare plays with potentially massive catalysts on the near-term horizon.

Wearable Health Solutions, Inc. (OTCMKTS: WHSI) crossed a major milestone earlier this summer when it finally announced the launch of its new 4G remote medical device.   This increased the company’s value by 30% showing that investors are in tune to this company’s development.  Now, there are 3 major catalysts on the horizon that could yield similar or even better results:

  • An anticipated uplisting
  • Major marketing push on Kathy Ireland’s business show, 
  • Projected increase in revenues due to the 4G launch

Other catalysts to monitor among speculative stocks in the healthcare space include several earnings dates this month:

  • G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) earnings are expected September 15th
  • Innovation Pharmaceuticals (OTCMKTS: IPIX) earnings are expected September 25th
  • Inventiva S.A. (Nasdaq: IVA) earnings are expected September 20th

CONCLUSIONHealthcare is arguably undervalued, several stocks are running based on catalysts; and there are more to come this month.  Speculative healthcare investors should start their research on WHSI, GMVD and IPIX.

Start your research here:

Disclaimers:  The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quotes; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.  CapitalGainsReport ‘CGR’ is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. CGR authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. CGR is compensated three thousand dollars monthly via wire transfer by Wearable Health Solutions to produce and syndicate content related to WHSI. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website.

Media Contact
Company Name: Capital Gains Report
Contact Person: Mark McKelvie
Email: Send Email
Country: United States